Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.54 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27827937 | 1.00 | TAS1R3 (0.54) | TAS1R3TAS1R1BIRC2POLBFOLH1 | |
| SCHEMBL15746392 | 0.92 | TAS1R3 (0.48) | TAS1R3TAS1R1BIRC2POLBFOLH1 | |
| SCHEMBL14902193 | 0.86 | L3MBTL1 (0.50) | TAS1R3TAS1R1BIRC2POLBMME | |
| SCHEMBL27909811 | 0.85 | TAS1R3 (0.54) | TAS1R3TAS1R1BIRC2POLBFOLH1 | |
| SCHEMBL27909770 | 0.85 | TAS1R3 (0.54) | TAS1R3TAS1R1BIRC2POLBFOLH1 | |
| SCHEMBL23106760 | 0.85 | TAS1R3 (0.54) | TAS1R3TAS1R1BIRC2POLBFOLH1 | |
| SCHEMBL11763539 | 0.85 | TAS1R3 (0.54) | TAS1R3TAS1R1BIRC2POLBFOLH1 | |
| SCHEMBL4246400 | 0.85 | TAS1R3 (0.54) | TAS1R3TAS1R1BIRC2POLBFOLH1 | |
| SCHEMBL15746403 | 0.84 | TAS1R3 (0.40) | TAS1R3TAS1R1BIRC2POLBFOLH1 | |
| SCHEMBL18633379 | 0.84 | TAS1R3 (0.53) | TAS1R3TAS1R1BIRC2POLBFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
| CN-101906069-B | (S)-2-substituted-(3'-acetyl-2'-pyridone-1'-yl) acetic acid as well as preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-12-12 | — | — | CN | disclosed |
| CN-101906069-A | (S)-2-substituted-(3'-acetyl-2'-pyridone-1'-yl) acetic acid as well as preparation method and application thereof | UNIV CAPITAL MEDICAL | 2010-12-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | TAS1R3 2683/4885TAS1R1 3766/4885BIRC2 3968/4885 |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | TAS1R3 2683/4885TAS1R1 3766/4885BIRC2 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.